Equillium, Inc.

How big is Equillium, Inc.?

As of Jun 18, Equillium, Inc. has a market capitalization of 11.79 million, categorizing it as a Micro Cap company, with net sales of 30.40 million and a net profit of -13.98 million over the latest four quarters.

Market Cap: As of Jun 18, Equillium, Inc. has a market capitalization of 11.79 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Equillium, Inc. reported net sales of 30.40 million and a net profit of -13.98 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 19.06 million and total assets of 25.73 million.

What does Equillium, Inc. do?

Equillium, Inc. is a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, with a market cap of $11.79 million and a recent net profit of -$9 million. The company is categorized as a micro-cap and has no dividend yield.

Overview: <BR>Equillium, Inc. is a biotechnology company that develops products for severe autoimmune and inflammatory disorders, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 11.79 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.36 <BR>Return on Equity: -132.23% <BR>Price to Book: 1.11<BR><BR>Contact Details: <BR>Address: 2223 Avenida de La Playa Ste 105, LA JOLLA CA: 92037-3217 <BR>Tel: 1 858 4125302 <BR>Website: http://equilliumbio.com/

Should I buy, sell or hold Equillium, Inc.?

Who are in the management team of Equillium, Inc.?

As of March 2022, the management team of Equillium, Inc. includes Executive Chairman Daniel Bradbury, President and CEO Bruce Steel, and Chief Scientific Officer Stephen Connelly, along with several independent directors.

As of March 2022, the management team of Equillium, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Bradbury, who serves as the Executive Chairman of the Board.<BR>- Mr. Bruce Steel, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Stephen Connelly, who holds the position of Chief Scientific Officer and is also a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Ms. Martha Demski, Dr. Bala Manian, Mr. Charles McDermott, and Dr. Mark Pruzanski. <BR><BR>In summary, as of March 2022, Equillium, Inc.'s management team consists of Mr. Daniel Bradbury, Mr. Bruce Steel, and Dr. Stephen Connelly, along with several independent directors.

Is Equillium, Inc. overvalued or undervalued?

As of March 23, 2023, Equillium, Inc. is considered risky and overvalued, with concerning financial metrics and a significant decline in stock performance compared to the S&P 500.

As of 23 March 2023, the valuation grade for Equillium, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.28, an EV to EBIT of 0.05, and an EV to EBITDA of 0.06, which suggest that the market may be pricing in more value than the underlying fundamentals support. <BR><BR>When compared to peers, Equillium's EV to EBITDA ratio of -4.9420 is significantly worse than OncoCyte Corp.'s -2.1276, highlighting a concerning valuation relative to its industry. Additionally, the company's recent stock performance shows a stark contrast to the S&P 500, with a 1-week return of -24.62% compared to the index's 1.05%, further reinforcing the notion that Equillium is currently overvalued.

Is Equillium, Inc. technically bullish or bearish?

As of September 5, 2025, Equillium, Inc. is in a bullish trend with strong indicators, but caution is advised due to a bearish RSI despite a year-to-date return of 100.48%.

As of 5 September 2025, the technical trend for Equillium, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on the weekly timeframe and bullish moving averages on the daily timeframe. However, the weekly RSI indicates bearish momentum, suggesting some caution. The stock has shown a strong year-to-date return of 100.48%, significantly outperforming the S&P 500's 12.22% over the same period. Overall, while the bullish indicators are strong, the mixed signals from the RSI warrant attention.